PARTNER at the 52nd Virtual Congress of the International Society of Paediatric Oncology (SIOP) – October 14-17, 2020
As the COVID-19 pandemic is spreading around the world, we are all facing a new reality affecting every one of us. This new reality changed our life on a personal as well as on a professional level. We are facing the need to change the way we interact with our patients and their families, and with each other- on local, national and international levels.
The web-based meeting platform enables us to continue to learn and to create collaborations to continue research and improving care.
This year, as part of this effort, the 52nd Virtual Congress of the International Society of Paediatric Oncology (SIOP 2020) will be held online on October 14-17, 2020. Our joint work, with the EXPeRT group and the PARTNER project, will be presented in 3 sessions in this meeting.
Dr D. Orbach, Dr A Ferrari and Pr M Ben-Harush and colleagues will present an E-poster with oral commentaries on the European experience of pediatric mesothelioma. D Orbach and colleagues were able to retrospectively analyse that, among pediatric patients with this very rare tumor, the combination of cisplatin-pemetrexed chemotherapy showed a real efficacy; surgical procedures combined with HIPEC therapy were associated with a favourable outcome and finally surgical treatments even in the setting of multiple relapses could be an option. The paper is submitted to a Peer-reviewed Journal (under revision) for publication.
Dr T Ben-Ami and colleagues will present the EXPeRT-PARTNER guidelines for the treatment of pediatric nasopharyngeal carcinoma (NPC) during an oral session. These guidelines represent the consensual experience and efforts of various national and international groups for the management of pediatric NPC, to improve outcome and reduce the significant treatment-related long-term effects.
Another example of the success of the EXPeRT-PARTNER collaboration is the presentation of guidelines for evaluation and treatment of pediatric adrenocortical tumors that will also be presented during an oral session by Dr C Virgone and colleagues. The guidelines establish the preferred surgical approach for patients with resectable disease at diagnosis and the recommendations for the use of mitotane and chemotherapy in patients with unresectable disease.
These works emphasize the value of continued collaboration of all pediatric oncologists, surgeons, and pathologists, especially for patients with very rare cancers. These efforts are essential to improve knowledge and care for our patients. The EXPeRT group and the PARTNER project supported by the European Union are key factors that will help us reach these goals.
PARTNER Project: The Project team met up for the Kick-off Meeting in Brussels
The Kick-off Meeting of the ERN-PAEDCAN Partner: Paediatric rare tumours network – European registry project was held just after the ERN PaedCan General Assembly on 2nd of February, 2018 in Brussels. PARTNER is one of the five projects funded by 3rd Health Programme. Five EU countries involved as Associated partners and 18 as Collaborating partners, including 9 Centres from Low Health Expenditure Average Rate (LHEAR) countries, 2 non EU countries and 1 parent’s organization work together and are looking for a novel solution in the field of virtual integrated healthcare system.
The project was judged innovative because it will create a Paediatric Rare Tumour European Registry (PARTNER) dedicated to children and adolescents with VRT (Very Rare Tumours) linking the existing national registries and providing a registry for those countries not already having a registry for VRT in place. The European Registry will be an essential part of the activity of the VRT subnetwork part of the ERN PaedCan. The possibility to link the registry with a virtual consultation system and the elaboration of diagnostic/treatment recommendations will create a platform that can be easily accessed by EU Health care providers. The increasing expertise in VRT based on the data collected in the European registry will increase the capacity to provide international consultation and define standard of treatment recommendations. This will ultimately result in improved patients’ care and reduce currently existing inequalities in cancer outcome across EU member states.
The project is funded from January 1st 2018 till 31st December 2018 and financed by the Consumers, Health, Agriculture and Food Executive Agency (Chafea) with a total budget of EUR 666,644.24. PARTNER projects team consists of Azienda Ospedaliera di Padova (IT), St. Anna Kinderkrebsforschung (AT), Klinikum Dortmund (DE), Karls Universitaet Tuebingen (DE), Institute Curie (FR), Gdanski Uniwersytet Medyczny (PL). PARTNER will be strongly promoted by SIOPE Clinical Research Council for paediatric and adolescent oncology (SIOPE CRC) which will implement the broad dissemination strategy of the project.
The Kick-off Meeting was welcomed by the Project Scientific Coordinator, Professor Gianni Bisogno, who presented PARTNER to the consortium starting from the Logo concept idea and the geographical distribution of the consortium members. Professor Gianni Bisogno gave an overview of the whole project, comprehensive of the tasks of each WP and Partner, and then each Leaders of work packages had the chance to present their organization, the role they will have and the activities they will carry out during the project.
A Technical round table followed, with the presentation of the challenges, objectives and the steps to be taken during the project, with a particular focus on the activities to be carried out in the next 12 months.
First Consortium Meeting of the PARTNER project
Luxembourg, 17th April 2018 – The PARTNER members gathered together for its 1st Consortium meeting after the project’s kick-off in February. The meeting, hosted by the CHAFEA, the Consumers, Health, Agriculture and Food Executive Agency, took place on 17th April 2018 in Luxembourg just after the Rare Diseases Registries Projects’ Kick-Off Meeting.
During the meeting issues concerning all the working groups and tasks are discussed. The leaders of the WPs presented the status of the works concerning their focus areas, then the whole consortium could continue the development in order to deliver the deliverables and achieve the milestones by the end of the first year of the project.
For what concerns the technical aspects of the PARTNER project, methodologic issues were raised and discussed, regarding both the drafting of VRT guidelines and the identification of a list of variables to be included in the European database. Among several options in use in the scientific community and reported in the literature, the more appropriate methodologies to drawing up guidelines for VRT have been elucidated and it has been collegially decided to circulate a document for the final approval. On the other hand, the list of variables is currently in progress, and it will be defined after the classification and evaluation of the lists of variables collected in the already existing national registries.
Second Consortium Meeting of the PARTNER project
Gdańsk, 14th September 2018 – The 2nd PARTNER Consortium Meeting was held in Gdańsk on the 14th of September 2018 in the first half of the day. The event has been hosted by the Gdanski Uniwersytet Medyczny (GUMed) team led by Dr. Ewa Bien at the Atheneum Gedanense Novum premises. Each partner involved in the PARTNER team has presented its achievements in the context its research activities and has assessed the general progress made on the project.
21 members of the 6 Associated partners and 6 Collaborating partners of the Consortium attended the meeting and collectively reviewed the Work Packages progress in the past months. The first session was devoted to six interesting and productive panels organised during the meeting allowing the participants for more insightful discussions.
The panels were devoted to the following topics:
WP1 Coordination of the project – Discussion on software development and sustainability requirements to address the user needs by reviewing a collection of User interface mock-ups proposed by consortium members.
WP2 Dissemination of the project – Review of project communication tools and events in order to improve communication through the implementation of community actions which are more visible and closer to patients.
WP3 Evaluation of the project – Feedback provided to project partners for corrective action: monitor-review-remedy model
WP4 Analysis and harmonization of data acquisition of the existing national VRT registries – Update on the state of acquisition of core and specific variables collected from the four national registry (TREP, FRACTURE, STEP and Polish Registry). Integration of the set of common data elements in the PARTNER registry has been discussed in order to adhere to ERDRI requests (European Platform of rare diseases registries). Identification of the VRT entities that should be included in the EU registry. Definition of general data sheet for the PARTNER registry that will be circulated and approved. Definition of which tumors would need specific forms: Nasopharyngeal Undifferentiated Carcinoma, Adrenocortical carcinoma, Salivary gland carcinoma and Melanoma have been chosen as first four tumors for which to create specific PARTNER guidelines and they will need specific forms as well. Furthermore, specific forms will be created with the help of Dr. Calogero Virgone: adrenocortical tumours, thyroid tumours, pheochromocytoma, appendix carcinoid, nasopharyngeal carcinoma, small intestine carcinoids, pulmonary blastoma. Some specific forms have already been prepared and been circulated for approval, together with the Data
Dictionary: Melanoma and skin tumours, Colorectal carcinoma, Salivary gland tumours, Pancreatic tumours, Mesothelioma, Thymoma and thymic carcinoma.
WP5 Creation of a European registry for paediatric patients with very rare tumours – PARTNER registry’s structure is presented and discussed. Embedding of EuPID in the registry is discussed. Data transfer from/to national registries is discussed. Integration of the set of common data elements in the PARTNER registry in order to adhere to ERDRI requests (European Platform of rare diseases registries) is underlined: definition of which variables (among the set of common data elements) are to be included and collected within the PARTNER project.
WP6 Standard of care recommendations for children with VRT – Definition of which tumours would need specific forms after survey done among partners: Nasopharyngeal Undifferentiated Carcinoma, Adrenocortical carcinoma, Salivary gland carcinoma and Melanoma have been chosen as first four tumors for which to create specific PARTNER guidelines. Working group have been created and methodology is discussed and approved (Consensus Conference Standard Operating procedures according the ESMO guidelines).
Professor Gianni Bisogno, Scientific Coordinator of the PARTNER project caught the attention of the consortium with valuable scientific recommendations and useful input for the dynamics and progress of the project.
The second session of the meeting organised by GUMed was focused on the Integration of LHEAR countries in the EU platform dedicated to VRT in paediatric age. The main discussion of the meeting was about the inclusion of LHEAR countries representatives in the elaboration of standard of treatment recommendations in collaboration with the Institute Curie (CURIE) lead of WP6. This collaboration will aim to make the standard of care recommendations as much as possible applicable in LHEAR countries and provide documents translation for better dissemination.
Finally, the consortium decided to meet again on February 2019.
Third Consortium Meeting of the PARTNER project
Brussels, 30th January 2019 – The 3rd PARTNER Consortium Meeting was held in Brussels on the 30th of January 2019 in the first half of the day. Nearly one year after the launch of the project, this event has been a great opportunity for participants to present the progress of their work and exchange on their findings and methodologies, as well as to plan future actions. This event has been organised by Prof. Gianni Bisogno (AOPD), Ines Brecht (EKUT) and Andrea Ferrari (EXPeRT), with the support of the SIOP Europe office.
The second session of the meeting organised by Dr. Ines Brecht (EKUT) was focused on Harmonization of data acquisition of the existing European registries. The main discussion of the 2nd Consensus meeting was about the national registries which must report the tumour entities and variables included in their national data registries. The final goal of the partners is to reach an agreement on the entities to be collected and the variables of the existing registries. This shall be done in close cooperation with AOPD (leading WP5) and IT experts who has been invited to attend the meeting.
The third meeting was organised by Dr. Andrea Ferrari (Istituto Nazionale per la Cura dei Tumori), chairman of the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT) and was focused on Group for Pediatric Rare Tumors (EXPeRT) and was focused on rules of membership and on the programme of the SIOP Europe 2019 Annual Meeting in Prague (May 2019) and on EXPeRT retrospective studies and publications (Salivary Gland Tumors, Mesothelioma, project on Molecular profiling for rare tumours). 30 members of the 30 Associated partners and 16 Collaborating partners of the Consortium attended the meetings and collectively reviewed the Work Packages progress in the past months.
Finally, the consortium decided to meet again on June 2019.
4th PARTNER Consortium Meeting
Tübingen, 7 June 2019 – The PARTNER Project Consortium was gathered in Tübingen for the 4th PARTNER Consortium Meeting. The event has been hosted by Eberhard Karls Universität Tübingen (EKUT) team led by Dr. Ines Brecht at the the Crona Hospitals of Tübingen. Topics included discussion of current status and plans for the coming series of collaborative activities as well as dissemination through future participation in conferences and publication of results. The advisory board members joined the general assembly session in the morning to get an overview of the course of the project. It was concluded that the first semester of PARTNER has been very successful. All project partners continue to have a high motivation to collaborate and to achieve high-level results. Technical results have already been achieved, which is also underlined by 3 journal papers and 8 conference papers submitted in the first project year. The work is running according to the schedule. The advisory board members expressed their satisfaction with the course of the project and provided valuable comments concerning exploitation and further activities.
The second part of the day was focused on IT Consensus meeting – Creation of a European registry for paediatric patients with very rare tumours and harmonized procedures of data registration organised by Dr. Ines Brecht. Technical IT matters and solutions were discussed, and fruitful outcomes emerged for the progress of the project implementation.
In total 21 representatives participated in the meetings, both personally and virtually, and all project partners were represented. The meetings were characterized by high motivation and a friendly and collaborative
Finally, the consortium decided to meet again in January/February 2020.
5th PARTNER Consortium Meeting and EKUT Round Table discussion
Brussels, 12 February 2020 – Following the four first consortium meetings, considerable progress has already been made. Project partners are now well set to move forward in the construction of a European Registry dedicated to children and adolescents with VRT linking existing national registries.
After an intense meeting between EXPeRT members on 11th February 2020, the PARTNER consortium held its 5th Consortium Meeting and EKUT Round Table discussion. These meetings took place in Brussels on the 12th of February 2020 and were hosted by SIOPE. Moderated by Prof. Gianni Bisogno, the consortium gathered to discuss the project advancements, agree on next steps, and continue to ensure alignment of project activities with the overall goals and the evolving European registry. During the project meeting, advancements in the development of a risk governance framework for the safety of registry were presented, alongside discussions on nature and its structure. The PARTNER members will build on the momentum created by the fruitful discussions during the M5 meeting to continue to develop the risk governance framework, as well as the structure of the registry, in partnership with the ERN PAEDCAN.
In total 34 representatives from 26 organisations participated in the meetings and all project partners were represented. The meetings were characterized by high motivation and a friendly and collaborative atmosphere. Many PARTNER members also plan to attend the upcoming 2nd Annual Meeting of SIOPE this May in Seville, the next ERN PAEDCAN GA in autumn and, and officially convene again for the next consortium meeting in June 2020!
In the meantime, stay tuned for more updates by following our newsletter via website www.siope.eu, and if you are an expert in the field and interested in participating as a stakeholder in the project, please visit the website https://www.raretumors-children.eu and/or write an email to email@example.com
- International Childhood Cancer Day (ICCD2018) at the European Parliament – 20.02.2018 Brussels – Belgium
- SIOPE – MAC (MEPs Against Cancer) at the European Parliament – 25.09.2018 Brussels, Belgium
- ESMO 2018 Congress – 19-23.10.2018 Munich, Germany
- SIOP 2018 Congress – 16-19.11.2018 Kyoto, Japan
- ERN-PAEDCAN General Assembly meetings – 01-02.02.2018 and 25-26.09.2018 Brussels, Belgium
- 9th CCI Europe Conference – 14.04.2018 Lisbon, Portugal
- 21th PanCare Conference – 18-20.04.2018 Prague, Czech Republic
- 22nd PanCare Conference – 24-26.10.2018 Paris, France
The results achieved and the tools developed within PARTNER are being disseminated through strategic collaborations (joint events, position papers, etc.) with organisations at European and international levels. These partner organisations reflect the target groups identified for PARTNER dissemination and are presented below:
- European Cancer Organisation (ECCO): Federation of professional cancer societies of which SIOPE is a member, regularly participating in the ECCO Cancer Congress with a variety of activities incl. PARTNER dissemination (during the reporting period: ECCO 2018 European Cancer Summit, September 2018);
- International Society of Paediatric Oncology (SIOP): of which SIOPE is a continental branch, participating in the annual international congress (during the reporting period: November 2018) with a variety of activities incl. PARTNER dissemination;
- SIOPE European Clinical Research Council for paediatric and adolescent oncology (SIOPE CRC): represents the paediatric oncology clinical research community across Europe. Established to facilitate good research practice exchange amongst international co-operative groups, this executive decision-making body expresses the unified voice by dealing with common burning issues in the field and by representing the point of view of National Paediatric Haemato-Oncology Societies (NaPHOS) and European Clinical Trial Groups (ECTGs) at the highest European political level with a variety of activities incl. PARTNER dissemination (during the reporting period: September 2018).